tbuckley/cabot-search huggingface dataset:
Influenza Vaccinations During the COVID-19 Pandemic — 11 U.S. Jurisdictions, September–December 2020
Authors: Patricia Castro Roman, Karen Kirtland, Elizabeth R. Zell, Nkenge Jones-Jack, Lauren Shaw, Lauren Shrader, Carrie Sprague, Jessica Schultz, Quan Le, Abhinav Nalla, Sydney Kuramoto, Iris Cheng, Mary Woinarowicz, Steve Robison, Shannon Robinson, Kelley Meder, Ashley Murphy, Lynn Gibbs-Scharf, LaTreace Harris, Bhavini Patel Murthy
Journal: MMWR Morbidity and Mortality Weekly Report (2021)

Influenza causes considerable morbidity and mortality in the United States. Between 2010 and 2020, an estimated 9-41 million cases resulted in 140,000-710,000 hospitalizations and 12,000-52,000 deaths annually (1). As the United States enters the 2021-22 influenza season, the potential impact of influenza illnesses is of concern given that influenza season will again coincide with the ongoing COVID-19 pandemic, which could further strain overburdened health care systems. The Advisory Committee on Immunization Practices (ACIP) recommends routine annual influenza vaccination for the 2021-22 influenza season for all persons aged ≥6 months who have no contraindications (2). To assess the potential impact of the COVID-19 pandemic on influenza vaccination coverage, the percentage change between administration of at least 1 dose of influenza vaccine during September-December 2020 was compared with the average administered in the corresponding periods in 2018 and 2019. The data analyzed were reported from 11 U.S. jurisdictions with high-performing state immunization information systems.* Overall, influenza vaccine administration was 9.0% higher in 2020 compared with the average in 2018 and 2019, combined. However, in 2020, the number of influenza vaccine doses administered to children aged 6-23 months and children aged 2-4 years, was 13.9% and 11.9% lower, respectively than the average for each age group in 2018 and 2019. Strategic efforts are needed to ensure high influenza vaccination coverage among all age groups, especially children aged 6 months-4 years who are not yet eligible to receive a COVID-19 vaccine. Administration of influenza vaccine and a COVID-19 vaccine among eligible populations is especially important to reduce the potential strain that influenza and COVID-19 cases could place on health care systems already overburdened by COVID-19.
Single-Cell Transcriptomics Study of Human Hematopoietic Progenitors Reveals Alterations Associated with Aging and Myeloid Malignancies
Authors: Marina Ainciburu, Teresa Ezponda, Nerea Berastegui, Ana Alfonso Pierola, Amaia Vilas-Zornoza, Patxi San Martin-Uriz, Diego Alignani, Jose Maria Lamo De Espinosa, Mikel San Julián, Tamara Jimenez, Felix López Cadenas, Sandra Muntion, Fermin Sanchez-Guijo, Antonieta Molero Yordi, María Julia Montoro, Guillermo Serrano, Aintzane Diaz-Mazkiaran, Miren Lasaga, Gomez-Cabrero David, Maria Diez-Campelo, David Valcarcel, Mikel Hernáez, Juan P. Romero, Felipe Prosper
Journal: Blood (2021)
Guided Ultrasound Opens Blood-Brain Barrier to Cancer Drugs
Authors: Jennifer Abbasi
Journal: JAMA (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 10831: Comparison of Clinical Outcomes in Transcatheter Aortic Valve Replacement with Edwards Sapien 3 versus Evolut Series: A Systematic Review and Meta-Analysis
Authors: Satyam Krishan, Khawaja Hassan Akhtar, Sardar H Ijaz, Ali Jafry, Sreeram Yalamanchili, Yusra M Nasir, Hafiza H Akhtar, Sourbha Dani
Journal: Circulation (2021)

Introduction: The third generation transcatheter heart valve system aimed to improve the safety of transcatheter aortic valve replacement (TAVR). We performed systematic review and meta-analysis to compare clinical outcomes after TAVR with Edwards Sapien 3 (ES3) and Evolut series (MER). Methods: A systematic search was conducted by 2 independent researchers in MEDLINE and EMBASE for studies comparing clinical outcomes after TAVR with ES3 and MER. 1 randomized controlled trial and 11 observational studies met the inclusion criteria. Mantel-Haenszel odds ratios were calculated, and for heterogeneity I 2 statistics were reported. Results: 12 studies with total 7,749 patients were included for final analysis. ES3 and MER were implanted in 4,333 and 3,416 patients respectively. ES3 showed statistically significant decrease in permanent pacemaker implantation at 30-days (OR: 0.60; 95% CI: 0.52-0.70; p&lt; 0.05). Furthermore, TAVR with ES3 showed non-statistically significant trend towards decreased all-cause mortality at 30 days (OR: 0.73; 95% CI: 0.51-1.02; p=0.07), and stroke at 30 days (OR: 0.55; 95% CI: 0.27-1.10; p=0.09). Cardiovascular mortality (OR: 1.03; 95% CI: 0.50-2.15; p=0.93), and acute kidney injury (OR: 1.08; 95% CI: 0.83-1.41; p=0.56) did not show statistically significant difference. Conclusions: While ES3 and MER had similar clinical outcomes, patients undergoing TAVR with ES3 had statistically significant decrease in permanent pacemaker implantation and hence may be favored in patients with pre-existing conduction system disease.
Initial Results of Phase I/II Study of Azacitidine in Combination with Quizartinib for Patients with Myelodysplastic Syndrome and Myelodysplastic/Myeloproliferative Neoplasm with <i>FLT3</i> or <i>CBL</i> Mutations
Authors: Tareq Abuasab, Elias J. Jabbour, Nicholas J. Short, Marina Konopleva, Kelly S. Chien, Shehab Fareed Mohamed, Naval Daver, Rashmi Kanagal-Shamanna, Hagop Kantarjian, Guillermo Garcia-Manero, Guillermo Montalban-Bravo
Journal: Blood (2021)
An Open-Source Toolkit That Powers the Genome-Wide Analysis of Mature B-Cell Lymphomas (GAMBL) Project
Authors: Kostiantyn Dreval, Bruno M. Grande, Helena Winata, Jasper Wong, Lakshay Sethi, Christopher K. Rushton, Prasath Pararajalingam, Sarah E. Arthur, Lauren C. Chong, Brett Collinge, Krysta M. Coyle, Manuela Cruz, Stacy Hung, Shaghayegh Soudi, Nicole Thomas, Christian Steidl, David W. Scott, Ryan D Morin, Laura K Hilton
Journal: Blood (2021)
Loss of the Base Excision Repair Gene <i>Apex1</i> Leads to Dysfunctional Adult Hematopoietic Stem and Progenitor Cells
Authors: Samantha Zaunz, Lukas Lauwereins, Manmohan Bajaj, Beatriz Guapo Neves, Francheska Cadacio, Lana Cleuren, Céline Notredame, Jurgen Marteijn, Kim De Keersmaecker, Catherine M. Verfaillie
Journal: Blood (2021)
Real-Life Survival Data after Triple-Exposure to Proteasome Inhibitors (PI), Immunomodulators (IMID) and Anti-CD38 in Multiple Myeloma Patients in the Emmy Cohort
Authors: Aurore Perrot, Cyrille Hulin, Margaret Macro, Laurent Frenzel, Carla Araujo, Philippe Moreau, Bruno Royer, Karim Belhadj, Denis Caillot, Xavier Leleu, Anne Vekhoff, Samantha Schulmann, Salomon Manier, Lionel Karlin, Laure Vincent, Sophie Rigaudeau, Driss Chaoui, Ronan Garlantezec, Nathalie Texier, Marion Willaime, Catherine Boccaccio, Olivier Decaux
Journal: Blood (2021)
The world according to covid vaccine coverage
Authors: Mun-Keat Looi
Journal: BMJ (2021)

<h3>Background</h3> Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical trials and cohort analyses have been published, which have the potential to change clinical care and therefore supporting the need to update the original recommendations. <h3>Methods</h3> Using EULAR standardised operating procedures for EULAR-endorsed recommendations, the EULAR task force undertook a systematic literature review and sought opinion from 20 experts from 13 countries. We modified existing recommendations and created new recommendations. <h3>Results</h3> Three overarching principles and 10 recommendations were formulated. We recommend that a suspected diagnosis of LVV should be confirmed by imaging or histology. High dose glucocorticoid therapy (40–60 mg/day prednisone-equivalent) should be initiated immediately for induction of remission in active giant cell arteritis (GCA) or Takayasu arteritis (TAK). We recommend adjunctive therapy in selected patients with GCA (refractory or relapsing disease, presence of an increased risk for glucocorticoid-related adverse events or complications) using tocilizumab. Methotrexate may be used as an alternative. Non-biological glucocorticoid-sparing agents should be given in combination with glucocorticoids in all patients with TAK and biological agents may be used in refractory or relapsing patients. We no longer recommend the routine use of antiplatelet or anticoagulant therapy for treatment of LVV unless it is indicated for other reasons. <h3>Conclusions</h3> We have updated the recommendations for the management of LVV to facilitate the translation of current scientific evidence and expert opinion into better management and improved outcome of patients in clinical practice.
A lysosome-targeted dextran-doxorubicin nanodrug overcomes doxorubicin-induced chemoresistance of myeloid leukemia
Authors: Yunxin Zeng, Xinyu Zhang, Dongjun Lin, Xiaohui Feng, Yuye Liu, Zhengwen Fang, Weijian Zhang, Yu Chen, Meng Zhao, Jun Wu, Linjia Jiang
Journal: Journal of Hematology & Oncology (2021)

Abstract The hypoxic microenvironment is presumed to be a sanctuary for myeloid leukemia cells that causes relapse following chemotherapy, but the underlying mechanism remains elusive. Using a zebrafish xenograft model, we observed that the hypoxic hematopoietic tissue preserved most of the chemoresistant leukemic cells following the doxorubicin (Dox) treatment. And hypoxia upregulated TFEB, a master regulator of lysosomal biogenesis, and increased lysosomes in leukemic cells. Specimens from relapsed myeloid leukemia patients also harbored excessive lysosomes, which trapped Dox and prevented drug nuclear influx leading to leukemia chemoresistance. Pharmaceutical inhibition of lysosomes enhanced Dox-induced cytotoxicity against leukemic cells under hypoxia circumstance. To overcome lysosome associated chemoresistance, we developed a pH-sensitive dextran-doxorubicin nanomedicine (Dex-Dox) that efficiently released Dox from lysosomes and increased drug nuclear influx. More importantly, Dex-Dox treatment significantly improved the chemotherapy outcome in the zebrafish xenografts transplanted with cultured leukemic cells or relapsed patient specimens. Overall, we developed a novel lysosome targeting nanomedicine that is promising to overcome the myeloid leukemia chemoresistance.
Microbial-Derived Metabolites Induce Epithelial Recovery Via the Sting Pathway in Mice and Men and Protect from Graft-Versus-Host Disease
Authors: Erik Thiele Orberg, Sascha Göttert, Andreas Hiergeist, Elisabeth Meedt, Karin Kleigrewe, Wolfgang Herr, Florian Bassermann, Andre Gessner, Ernst Holler, Simon Heidegger, Hendrik Poeck
Journal: Blood (2021)
Multiparametric Flow Cytometry Evaluation of CD200L/CD200R- LSC/NK Synapse Including Leukemia Stem Cell (LSC) Fraction As a Potential Therapeutic Target and Marker of NK Cell Exhaustion in Pediatric AML-Conect-AML French Collaborative Network
Authors: Adriana Plesa, Octavia Cadassou, Joris Gutrin, Marine Villard, Christophe Roumier, Meyling Cheok, Florent Dumezy, Claude Preudhomme, Hélène Lapillonne, Arnaud Petit, Guy Leverger, Carine Halfon-Domenech, Cecile Renard, Yves Bertrand, Charles Dumontet, Sebastien Viel, Veronique Maguer-Satta, Thierry Walzer
Journal: Blood (2021)
Organ-on-a-chip model of vascularized human bone marrow niches
Authors: Drew E. Glaser, Matthew B. Curtis, Peter A. Sariano, Zachary A. Rollins, Bhupinder S. Shergill, Aravind Anand, Alyssa M. Deely, Venktesh S. Shirure, Leif Anderson, Jeremy M. Lowen, Natalie R. Ng, Katherine Weilbaecher, Daniel C. Link, Steven C. George
Journal: Biomaterials (2021)
Nx-5948, a Selective Degrader of BTK with Activity in Preclinical Models of Hematologic and Brain Malignancies
Authors: Daniel W Robbins, Mark Noviski, Ryan Rountree, May Tan, Nivetha Brathaban, Timothy Ingallinera, Dane E Karr, Aileen Kelly, Zef Konst, Jun Ma, Austin Tenn-McClellan, Jenny McKinnell, Luz Perez, Cristiana Guiducci, Gwenn Hansen, Arthur Sands
Journal: Blood (2021)
Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
Authors: Anne Mea Spanjaart, Per Ljungman, Rafael de La Camara, Gloria Tridello, Valentín Ortiz-Maldonado, Alvaro Urbano-Ispizua, Pere Barba, Mi Kwon, Dolores Caballero, Pierre Sesques, Emmanuel Bachy, Roberta Di Blasi, Catherine Thieblemont, Friso Calkoen, Pim Mutsaers, Johan Maertens, Livia Giannoni, Emma Nicholson, Matthew Collin, Carlos Pinho Vaz, Elisabetta Metafuni, Joaquin Martinez-Lopez, Fiona L. Dignan, Josep-Maria Ribera, Arnon Nagler, Frantisek Folber, Robin Sanderson, Adrian Bloor, Fabio Ciceri, Nina Knelange, Francis Ayuk, Nicolaus Kroger, Marie José Kersten, Stephan Mielke
Journal: Leukemia (2021)

COVID-19 is posing a significant threat to health in vulnerable patients, such as immunocompromised patients.For hematopoietic cell transplantation (HCT) recipients and patients with hematologic malignancies it is known that COVID-19 leads to severe morbidity and high mortality as compared to the general population [1][2][3].For patients treated with Chimeric Antigen Receptor T-cell (CAR-T-cell) therapy for B-cell malignancies however, descriptions of the clinical course and outcome are still limited to small case series and case reports [4][5][6][7][8].CAR-T-cell therapy recipients are believed to be at high risk of poor outcomes from COVID-19 due to their severely immunocompromised state, caused by prior lymphodepleting immunochemotherapy and CAR-T-cell therapy related side effects such as B-cell depletion, hypogammaglobulinemia, and cytopenias.In order to rapidly inform the medical field on the impact of COVID-19 on CAR-T-cell therapy recipients, the EBMT Infectious Diseases Working Party and the EHA Lymphoma Group joined forces and present the clinical course of COVID-19 in the largest European cohort to date.In response to the COVID-19 pandemic, the EBMT developed a special report form to conduct a multicenter survey study on patients with COVID-19 after CAR-T-cell therapy for hematologic malignancies (Fig. S1).Only PCR positive SARS-CoV-2 diagnosed
Mobile devices and wearable technology for measuring patient outcomes after surgery: a systematic review
Authors: Stephen R. Knight, Nathan Ng, Athanasios Tsanas, Kenneth Mclean, Claudia Pagliari, Ewen M. Harrison
Journal: npj Digital Medicine (2021)

Complications following surgery are common and frequently occur the following discharge. Mobile and wearable digital health interventions (DHI) provide an opportunity to monitor and support patients during their postoperative recovery. Lack of high-quality evidence is often cited as a barrier to DHI implementation. This review captures and appraises the current use, evidence base and reporting quality of mobile and wearable DHI following surgery. Keyword searches were performed within Embase, Cochrane Library, Web of Science and WHO Global Index Medicus databases, together with clinical trial registries and Google scholar. Studies involving patients undergoing any surgery requiring skin incision where postoperative outcomes were measured using a DHI following hospital discharge were included, with DHI defined as mobile and wireless technologies for health to improve health system efficiency and health outcomes. Methodological reporting quality was determined using the validated mobile health evidence reporting and assessment (mERA) guidelines. Bias was assessed using the Cochrane Collaboration tool for randomised studies or MINORS depending on study type. Overall, 6969 articles were screened, with 44 articles included. The majority (n = 34) described small prospective study designs, with a high risk of bias demonstrated. Reporting standards were suboptimal across all domains, particularly in relation to data security, prior patient engagement and cost analysis. Despite the potential of DHI to improve postoperative patient care, current progress is severely restricted by limitations in methodological reporting. There is an urgent need to improve reporting for DHI following surgery to identify patient benefit, promote reproducibility and encourage sustainability.
Abstract PR04: Decoding tumor microenvironment to enhance NSCLC targeted therapy
Authors: Haichuan Hu, Lecia Sequist, Zofia Piotrowska, Hillary Mulvey, Sundus Noeen, Patricia Hare, David Kodack, Aaron Hata, Matt Niederst, Cyril Benes, Jeff Engelman
Journal: Clinical Cancer Research (2018)

Abstract Background: Tyrosine kinase inhibitors (TKI) have yielded promising responses in non-small cell lung cancer (NSCLC) with EGFR mutations and ALK translocations. However, these and other targeted therapies are limited by intrinsic and acquired drug resistance. The previous study from our group investigated tumor autonomous resistance mechanisms by developing patient-derived cancer models (PDCs). In this study, we aimed to decipher the nonautonomous resistance mechanisms via tumor microenvironment by developing patient-derived fibroblast (PDF) models. Method: Cancer-associated fibroblast cell lines are established directly from individual EGFR mutant NSCLC biopsies. These cell lines, as representative of each patient’s tumor microenvironment, are further subjected to functional analysis. An imaging-based high-throughput platform is developed to screen for nonautonomous resistance by co-culturing PDC and PDF models in vitro. In the parallel, two independent approaches are performed to further identify mechanisms underlying the nonautonomous resistance. These include a drug screen to determine the pathway maintaining the cancer cells’ survival, and a secretomic analysis on the PDFs to identify the plausible cytokine(s) responsible for the resistance. Result: By co-culturing screening, nonautonomous resistance can be found in a wide spectrum of models. The subsequent drug screen reveals both a canonical HGF-dependent and novel HGF-independent mechanisms contributing to EGFR TKI resistance. Both of these can be explained by the PDF’s variable cytokine secretion and can be overcome by specific therapeutic combinations. Moreover, the microenvironment-driven EGFR TKI resistance has also been validated in vivo. The prevalence of the identified cytokine is further tested in clinical specimens. Conclusion: PDFs provide a new avenue to explore nonautonomous resistance for targeted therapy. Applying this approach, we identified both the canonical HGF-dependent and novel HGF-independent mechanisms that putatively confer EGFR TKI resistance. Taking EGFR TKI therapy as a paradigm, these findings will be valuable to optimize targeted therapy and to inform the design of personalized pharmaceutical interventions. This abstract is also being presented as Poster B25. Citation Format: Haichuan Hu, Lecia Sequist, Zofia Piotrowska, Hillary Mulvey, Sundus Noeen, Patricia Hare, David Kodack, Aaron Hata, Matt Niederst, Cyril Benes, Jeff Engelman. Decoding tumor microenvironment to enhance NSCLC targeted therapy [abstract]. In: Proceedings of the Fifth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic; Jan 8-11, 2018; San Diego, CA. Philadelphia (PA): AACR; Clin Cancer Res 2018;24(17_Suppl):Abstract nr PR04.
Daratumumab Plus Ixazomib, Lenalidomide, and Dexamethasone As Extended Induction and Consolidation Followed By Lenalidomide Maintenance in Standard-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (IFM 2018-01): A Phase II Study of the Intergroupe Francophone Du Myélome (IFM)
Authors: Aurore Perrot, Valérie Lauwers-Cances, Cyrille Touzeau, Olivier Decaux, Cyrille Hulin, Magaret Macro, Anne-Marie Stoppa, Marie Lorraine Chretien, Lionel Karlin, Clara Mariette, Caroline Jacquet, Murielle Roussel, Coralie Guillemot, Laure Devlamynck, Hervé Avet-Loiseau, Philippe Moreau, Michel Attal
Journal: Blood (2021)
Abstract 13054: Cxcl12 Activation Induces Pericyte Dissociation and Small Vessel Loss in PAH
Authors: Ke Yuan, Vinicio de Jesus Perez, Yu Liu, Abinaya Nathan, David Condon, Serena Zhang
Journal: Circulation (2019)

Background: Pericytes are specialized perivascular cells that directly interact with endothelial cells (EC) in capillaries. Our group and others have shown that human pericytes from patients with p...
Abstract 10201: Efficacy of Mavacamten in Patients with Symptomatic Hypertrophic Cardiomyopathy: Sub-Group Analyses by Background Beta-Blocker Use from the EXPLORER-HCM and MAVA-LTE Studies
Authors: Daniel L Jacoby, Matthew T Wheeler, Perry M Elliott, Sara Saberi, Amy J Sehnert, Jay M Edelberg, Wanying Li, iacopo olivotto
Journal: Circulation (2021)

Introduction: Mavacamten, a selective inhibitor of cardiac myosin, improved symptoms and exercise capacity (pVO 2 ) in adults with obstructive hypertrophic cardiomyopathy (oHCM) (EXPLORER-HCM; NCT03470545). Improvements in pVO 2 were observed regardless of whether patients were receiving beta-blockers (BB), but were greater in those not receiving BB. To examine whether BB lessen the effect of mavacamten on other parameters such as function, echocardiographic parameters, biomarkers and symptoms further sub-group analyses of EXPLORER-HCM and the mavacamten long-term extension (MAVA-LTE; NCT03723655) studies were conducted. Methods: In the phase 3, placebo-controlled EXPLORER-HCM trial, randomization was stratified by BB usage, and pre-specified sub-group analyses were performed. MAVA-LTE is an ongoing study evaluating long-term mavacamten dosing in patients with HCM who completed EXPLORER-HCM or MAVERICK. Sub-group analyses by BB usage for the same endpoints, if available, were performed post hoc including only patients with oHCM. Results: Results are shown in the Table. In EXPLORER-HCM, the majority of patients not taking BB received non-dihydropyridine calcium channel blockers (mavacamten [25/29 patients] or placebo [17/33]); this trend continued in MAVA-LTE. In EXPLORER-HCM, the mean change from baseline in pVO 2 was lower in the sub-group using BB (1.1 ml/kg/min) vs not using BB (2.2 ml/kg/min), while the heart rate-independent parameter, VE/VCO 2 slope (ventilatory efficiency), improved similarly in both groups (-2.4 vs -2.7). Improvements in symptoms (NYHA Class, KCCQ-CSS), LVOT gradients, LAVI, and biomarkers (NT-proBNP and cTnI) were similar between subgroups across both studies. Conclusion: In EXPLORER-HCM, the reduced effect of mavacamten on pVO2 in BB users is likely due to the effect of BB on heart rate response during exercise. Mavacamten benefits were observed across a range of clinically meaningful parameters regardless of BB use.